Standard BioTools Mails Proxy for Treeline Reverse Merger; Nov 19 Vote Set
LAB is trading near its 52-week low of $0.618 (5.2% above the low) on light trading volume (0.3× avg).
Summary
Standard BioTools mailed the definitive proxy for its reverse merger with Treeline, setting a November 19, 2026 shareholder vote. Existing holders would own about 16% of the combined company, with up to 2.0 billion new shares issued and net tangible book value per share dropping from $1.38 to $0.43.
Key Events · M&A and Partnerships · LAB
-
Definitive Proxy Mailed for Treeline Merger
A Special Meeting is set for November 19, 2026, with a record date of October 16, 2026; shareholders will vote on the share issuance, a 1-for-20 to 1-for-40 reverse split, and the Element mass cytometry divestiture.
-
Massive Dilution to Existing Holders
Up to 2,007,493,452 shares will be issued in the Merger, about 70.7% of the pro forma fully diluted share count pre-split; former Standard BioTools holders will own roughly 16% of the combined company versus 84% for Treeline holders.
-
Book Value Per Share Falls Sharply
Net tangible book value drops from $1.38 to $0.43 per share pro forma, a $0.95 per share decrease to existing Standard BioTools stockholders.
-
CVRs and Legacy Asset Sales
Holders receive one CVR per share, capped at 76,000,000 shares, tied to proceeds from the $5.5 million Element mass cytometry sale and the pending microfluidics divestiture to ARCHIMED.
Analysis · LAB · Life Sciences
The definitive proxy/prospectus for the all-stock reverse merger with Treeline Biosciences puts hard numbers on what existing holders are giving up. On a fully diluted basis, Standard BioTools shareholders will own roughly 16% of the combined company while Treeline holders take about 84%, and up to 2.0 billion shares will be issued in the deal — about 70.7% of the pro forma fully diluted share count before the reverse split. Net tangible book value per share falls from $1.38 to $0.43, a $0.95 hit to current holders. In exchange, Standard BioTools contributes roughly $450 million of net cash and its legacy mass cytometry and microfluidics businesses are being sold off, with holders receiving CVRs for up to 76 million shares tied to those proceeds. The vote is November 19, 2026, and approval of the share issuance and the 1-for-20 to 1-for-40 reverse split is required for the deal to close; a failure to approve triggers a $16.1 million termination fee. The filing also discloses July and August 2026 shareholder demand letters alleging the proxy omits material information — a litigation overhang ahead of the vote.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 43.9% of the 285 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LAB was trading at $0.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $255.2M. The 52-week trading range was $0.62 to $1.72. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.